KBC Group NV Has $86,000 Stock Position in Geron Co. (NASDAQ:GERN)

KBC Group NV increased its position in shares of Geron Co. (NASDAQ:GERN) by 45.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,414 shares of the biopharmaceutical company’s stock after acquiring an additional 7,592 shares during the quarter. KBC Group NV’s holdings in Geron were worth $86,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GERN. Readystate Asset Management LP acquired a new stake in shares of Geron during the third quarter worth $58,000. Rovin Capital UT ADV grew its position in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares during the period. Monterey Private Wealth Inc. bought a new stake in shares of Geron in the 4th quarter valued at about $63,000. Empowered Funds LLC bought a new stake in shares of Geron in the 3rd quarter valued at about $67,000. Finally, Inspire Advisors LLC acquired a new stake in shares of Geron in the 3rd quarter valued at approximately $68,000. Institutional investors own 73.71% of the company’s stock.

Geron Price Performance

NASDAQ:GERN opened at $2.93 on Monday. The stock has a 50-day simple moving average of $3.37 and a 200 day simple moving average of $3.99. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a market cap of $1.77 billion, a PE ratio of -9.16 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. The company had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same period last year, the business earned ($0.08) EPS. On average, sell-side analysts expect that Geron Co. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on GERN. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. Barclays raised shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. Needham & Company LLC raised their price objective on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, Scotiabank began coverage on Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.25.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.